This trial is active, not recruiting.

Condition osteoarthritis
Treatments 0.2% ropivacaine, 0.9% normal saline
Phase phase 4
Sponsor Mayo Clinic
Start date October 2015
End date October 2016
Trial size 102 participants
Trial identifier NCT02576249, 15-003120


Corticosteroid injections are commonly used for the symptomatic treatment of knee osteoarthritis. Common practice is to inject the joint with a combination of corticosteroid and local anesthetic, with the rationale of providing longer duration pain relief with the corticosteroid and immediate, though short duration relief with the anesthetic. However, multiple in vitro and animal studies have shown that local anesthetic may be harmful to chondrocytes. Despite this data, use of intra-articular anesthetic remains widespread. Many clinicians believe incorporating the anesthetic is important because it can provide immediate pain relief and facilitate patient confidence in the treatment program. However, there is no published data to validate this reasoning. Therefore, the anesthetic has unknown clinical benefit and may have adverse effects on articular cartilage. In light of this, the investigators question the routine use of anesthetics in joint injections. The purpose of this study is to compare the effects of knee joint injections using: 1) corticosteroid with local anesthetic versus 2) corticosteroid with normal saline.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification bio-equivalence study
Intervention model parallel assignment
Masking double blind (subject, investigator, outcomes assessor)
Primary purpose treatment
(Active Comparator)
0.2% ropivacaine and methylprednisolone knee joint injection
0.2% ropivacaine Naropin
0.9% normal saline and methylprednisolone knee joint injection
0.9% normal saline sodium chloride

Primary Outcomes

time frame: 2 weeks

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion criteria: 1. age 18 or older 2. knee osteoarthritis (uni- or bilateral) as defined by the American College of Rheumatology (staged by Kellgren-Lawrence radiographic grading scale) Exclusion criteria: 1. rheumatologic/inflammatory disease 2. metabolic bone disease 3. crystalline arthropathy 4. current smoking 5. BMI > 40 6. knee injection with corticosteroid or viscosupplementation within previous 6 months 7. history of knee prolotherapy, platelet rich plasma or cellular (stem cell) injection 8. knee surgery within the last year 9. chronic opioid use 10. chronic pain syndrome/fibromyalgia 11. pain behavior during the clinical encounter as judged by the injecting physician 12. physician specifically orders injection of corticosteroid/anesthetic or other specific combined corticosteroid injection 13. diagnostic uncertainty by referring provider 14. referral for bilateral knee or multiple joint injections (*note that arthritis involving multiple joints alone is not an exclusion criteria, only the patient receiving more than 1 injection)

Additional Information

Official title Does Anesthetic Contribute to Symptomatic Relief in Corticosteroid Injections for Knee Osteoarthritis? A Double-Blind Randomized Trial Comparing Corticosteroid/Ropivacaine Versus Corticosteroid/Saline Injections
Principal investigator Jacob L Sellon, MD
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by Mayo Clinic.